HanAll Biopharma stock: Partner's arthritis trial hits primary goal
Published on 11/18/2026 at 00:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical milestone and next steps
- Immunovant reported that imeroprubart met the primary endpoint in difficult-to-treat rheumatoid arthritis.
- The high-dose group showed a stronger ACR20 response than placebo at Week 28.
- Immunovant plans to discuss further development with the US Food and Drug Administration by year-end.
- Topline results in Graves' disease and myasthenia gravis are expected in 2027.
HanAll Biopharma's global partner Immunovant said on November 10 that imeroprubart, also known as IMVT-1402, met the primary endpoint in a Phase 2b trial for patients with difficult-to-treat rheumatoid arthritis. The result came from Immunovant's quarterly earnings announcement and was reported by The Asia Business Daily.
High-dose response exceeds placebo
The study enrolled patients whose symptoms had not improved after treatment with at least two targeted therapies using different mechanisms. In the second part of the trial, patients received 600 milligrams, 300 milligrams or placebo for another 12 weeks after an initial treatment period.
At Week 28, the 600-milligram group recorded an ACR20 response rate of 92.5%, compared with 75.6% for placebo. The difference was statistically significant, with a p-value of 0.0139. Exploratory ACR50 and ACR70 response rates in the high-dose group reached 80% and 52.5%, respectively.
FDA discussions planned this year
The secondary Clinical Disease Activity Index and Simplified Disease Activity Index endpoints did not show statistically significant differences. No serious adverse events or treatment discontinuations caused by adverse events were reported in the study.
Immunovant plans to discuss the next development steps for difficult-to-treat rheumatoid arthritis with the US Food and Drug Administration by the end of 2026. Results from imeroprubart trials in Graves' disease and myasthenia gravis are expected in 2027, while data from a chronic inflammatory demyelinating polyneuropathy trial are expected in 2028.
HanAll's therapeutic focus
HanAll Biopharma develops medicines for unmet medical needs. Its therapeutic focus includes ophthalmology, immunology, oncology and neurology, with pipeline programs including the anti-FcRn antibody batoclimab and imeroprubart. The company presents its research pipeline and therapeutic areas on its corporate website.
HanAll Biopharma at a glance
- Company: HanAll Biopharma
- ISIN: KR7009420001
- KRX ticker: 009420.KS
- Therapeutic areas: Ophthalmology, immunology, oncology and neurology
South Korean biotechnology and pharmaceutical shares remain part of the broader KOSPI market environment.
More news and analyses on HanAll Biopharma stock.
